China's NCDS and PerkinElmer, Inc. (PKI) Set Up Biomarker Partnership  
4/15/2013 9:45:00 AM

by Richard Daverman, PhD

April 12, 2013 -- The National Center for Drug Screening of China, located in Shanghai’s Zhangjiang Hi-Tech Park, will collaborate with PerkinElmer to validate new diagnostic tests for diabetes in Asian populations. Their partnership will be called the Translational Medicine Collaboration Center. Using next-generation sequencing technologies, the Center will seek to bring personalized medicine concepts to diabetes treatment in China. More details....

Stock Symbol: (NYSE: PKI)